Our Team
A management team with decades of experience in biotechnology, drug development, and company building.
Management Team
Fred M. Schwarzer
Executive Chairman
Mr. Schwarzer is an experienced biotechnology executive and investor with extensive leadership across public and private life sciences companies.
Mr. Schwarzer previously served as Chief Executive Officer of IGM Biosciences, a clinical-stage biotechnology company focused on novel antibody therapeutics for oncology. Mr. Schwarzer was also a founder of Charter Life Sciences, a venture capital firm specializing in life sciences investments, where he served as Managing Partner for more than 15 years.
Mr. Schwarzer also served as Chief Executive Officer and Chairman of Heska Corporation, Chairman of Inviragen, Inc. from its first institutional investment round through its acquisition by Takeda Pharmaceutical Company, and Chairman of Visioneering Technologies.
Mr. Schwarzer holds a BA from the University of Michigan and a JD from the University of California, Berkeley School of Law.
Stephen Snowdy, PhD, MBA
Chief Executive Officer
Dr. Snowdy is a biotechnology and medical device executive with more than 25 years of experience leading companies from early concept through global commercialization in both public and private settings. His career includes capital formation, IPO execution, post-IPO investor relations, and executive leadership across diverse therapeutic areas including oncology, gene therapy, cardiovascular disease, ophthalmology, and pain.
Dr. Snowdy previously served as Chief Executive Officer of LadRx Corporation, a targeted oncology therapeutic company through the out-license of its Phase 3 ready drug candidate. Dr. Snowdy also served as Chief Executive Officer of Visioneering Technologies, a development and commercial stage company addressing the pediatric myopia progression and presbyopia markets.
Dr. Snowdy was also previously a Partner of MB Venture Partners, where for eight years he focused on early-stage biotechnology and medical device investments.
Dr. Snowdy holds a PhD in Neurobiology from the University of North Carolina at Chapel Hill (UNC), an MBA from UNC, and a BS in Chemistry from the University of Florida.
Bruce Keyt, PhD
Chief Scientific Officer
Dr. Keyt has over four decades of experience in biopharmaceutical research, development, and leadership across both large and emerging biotechnology companies. His expertise spans target discovery, in vitro and in vivo pharmacology, preclinical development, and the advancement of biologics and protein-based therapeutics.
Dr. Keyt previously served as Chief Scientific Officer of IGM Biosciences, a clinical stage biotechnology company focused on novel antibody therapeutics for oncology.
Dr. Keyt has also held senior scientific leadership roles at Genentech, Millennium Pharmaceuticals and Abgenix. He has made significant contributions to the development of multiple approved biologic therapies and is a co-author of more than 55 scientific publications and a co-inventor on over 35 U.S. patents and patent applications.
Dr. Keyt holds a PhD in Biochemistry and Pharmacology from Tufts University School of Medicine and a BS degree in Chemistry from Washington University in St. Louis.
Board of Directors
Bruce Keyt, PhD
Chief Scientific Officer
Dr. Keyt has over four decades of experience in biopharmaceutical research, development, and leadership across both large and emerging biotechnology companies. His expertise spans target discovery, in vitro and in vivo pharmacology, preclinical development, and the advancement of biologics and protein-based therapeutics.
Dr. Keyt has held senior scientific leadership roles at companies including Genentech, Millennium Pharmaceuticals, Abgenix, and IGM Biosciences, where he previously served as Chief Scientific Officer. He has made significant contributions to the development of multiple approved biologic therapies and is a co-author of more than 55 scientific publications and a co-inventor on over 35 U.S. patents and patent applications. Dr. Keyt earned his PhD in Biochemistry and Pharmacology from Tufts University School of Medicine and a bachelor’s degree in chemistry from Washington University in St. Louis.
Bruce Keyt, PhD
Chief Scientific Officer
Bio:
Dr. Keyt has over four decades of experience in biopharmaceutical research, development, and leadership across both large and emerging biotechnology companies. His expertise spans target discovery, in vitro and in vivo pharmacology, preclinical development, and the advancement of biologics and protein-based therapeutics.
Dr. Keyt has held senior scientific leadership roles at companies including Genentech, Millennium Pharmaceuticals, Abgenix, and IGM Biosciences, where he previously served as Chief Scientific Officer. He has made significant contributions to the development of multiple approved biologic therapies and is a co-author of more than 55 scientific publications and a co-inventor on over 35 U.S. patents and patent applications. Dr. Keyt earned his PhD in Biochemistry and Pharmacology from Tufts University School of Medicine and a bachelor’s degree in chemistry from Washington University in St. Louis.
Bruce Keyt, PhD
Chief Scientific Officer
Bio:
Dr. Keyt has over four decades of experience in biopharmaceutical research, development, and leadership across both large and emerging biotechnology companies. His expertise spans target discovery, in vitro and in vivo pharmacology, preclinical development, and the advancement of biologics and protein-based therapeutics.
Dr. Keyt has held senior scientific leadership roles at companies including Genentech, Millennium Pharmaceuticals, Abgenix, and IGM Biosciences, where he previously served as Chief Scientific Officer. He has made significant contributions to the development of multiple approved biologic therapies and is a co-author of more than 55 scientific publications and a co-inventor on over 35 U.S. patents and patent applications. Dr. Keyt earned his PhD in Biochemistry and Pharmacology from Tufts University School of Medicine and a bachelor’s degree in chemistry from Washington University in St. Louis.
Chris Takamoto
Board Member (Pending Final Confirmation)
Bio:
Dr. Keyt has over four decades of experience in biopharmaceutical research, development, and leadership across both large and emerging biotechnology companies. His expertise spans target discovery, in vitro and in vivo pharmacology, preclinical development, and the advancement of biologics and protein-based therapeutics.
Dr. Keyt has held senior scientific leadership roles at companies including Genentech, Millennium Pharmaceuticals, Abgenix, and IGM Biosciences, where he previously served as Chief Scientific Officer. He has made significant contributions to the development of multiple approved biologic therapies and is a co-author of more than 55 scientific publications and a co-inventor on over 35 U.S. patents and patent applications. Dr. Keyt earned his PhD in Biochemistry and Pharmacology from Tufts University School of Medicine and a bachelor’s degree in chemistry from Washington University in St. Louis.
Misbah Tahir
Board Member (Pending Final Confirmation)
Bio:
Dr. Keyt has over four decades of experience in biopharmaceutical research, development, and leadership across both large and emerging biotechnology companies. His expertise spans target discovery, in vitro and in vivo pharmacology, preclinical development, and the advancement of biologics and protein-based therapeutics.
Dr. Keyt has held senior scientific leadership roles at companies including Genentech, Millennium Pharmaceuticals, Abgenix, and IGM Biosciences, where he previously served as Chief Scientific Officer. He has made significant contributions to the development of multiple approved biologic therapies and is a co-author of more than 55 scientific publications and a co-inventor on over 35 U.S. patents and patent applications. Dr. Keyt earned his PhD in Biochemistry and Pharmacology from Tufts University School of Medicine and a bachelor’s degree in chemistry from Washington University in St. Louis.